恶性血液病单倍型造血干细胞移植中ATG剂量的优化
该回顾性研究纳入288例接受单倍型造血干细胞移植的恶性血液病患者,按预处理方案中兔抗人胸腺细胞球蛋白(rATG)总量分为6、7.5、9 mg/kg三组,比较急性移植物抗宿主病(GVHD)、感染及生存情况,发现低剂量(6 mg/kg)可能增加Ⅱ~Ⅳ度急性GVHD风险,高剂量(9 mg/kg)使巨细胞病毒(CMV)和EB病毒(EBV)感染风险增加,中剂量(7.5 mg/kg)可能是兼顾降低中重度急性GVHD和病毒感染发生率的选择。
要点
- 低剂量rATG(6 mg/kg)可能增加单倍型移植后Ⅱ~Ⅳ度急性GVHD的发生率。
- 高剂量rATG(9 mg/kg)使CMV、EBV感染风险增加。
- 中剂量rATG(7.5 mg/kg)可能是兼顾降低中重度急性GVHD和病毒感染发生率的选择。
核心结论
- 低剂量rATG(6 mg/kg)可增加单倍型造血干细胞移植后Ⅱ~Ⅳ度急性GVHD的发生率。
- 高剂量rATG(9 mg/kg)使CMV、EBV感染风险增加。
- 中剂量rATG(7.5 mg/kg)可能是兼顾降低中重度急性GVHD和病毒感染发生率的选择。
研究设计与样本
- 回顾性分析2013年3月至2018年12月在本院接受单倍型造血干细胞移植的恶性血液病患者。
- 按预处理方案中rATG总量6、7.5、9 mg/kg分为ATG-6组(159例)、ATG-7.5组(72例)、ATG-9组(57例),共288例。
主要发现
- 纳入288例患者,男182例、女106例,中位年龄18(6~62)岁;急性髓系白血病128例、急性淋巴细胞白血病110例、慢性髓性白血病8例、骨髓增生异常综合征28例、混合细胞白血病14例。
- 移植后中位随访时间14.0(0.2~74.0)个月。
- ATG-6、ATG-7.5、ATG-9组粒细胞植入率分别为96.9%、97.2%、96.5%(P=0.972),血小板植入率分别为92.5%、87.5%、86.0%(P=0.276)。
- ATG-6、ATG-7.5、ATG-9组Ⅱ~Ⅳ度急性GVHD发生率分别为14.5%、11.1%、8.8%(P=0.493),慢性GVHD发生率分别为8.8%、14.3%、12.0%(P=0.493)。
- ATG-9组CMV、EBV感染率(77.2%、12.5%)均高于ATG-6组(43.3%、3.5%)和ATG-7.5组(44.4%、1.5%)(P<0.001,P=0.033)。
关键数值与推荐
- ATG-6、ATG-7.5、ATG-9组3年总生存率分别为68.5%(95%CI 60.3%~77.9%)、60.1%(95%CI 48.3%~74.8%)、64.7%(95%CI 51.9%~80.7%)(P=0.648)。
- ATG-6、ATG-7.5、ATG-9组3年累积复发率分别为34.6%(95%CI 34.3%~35.1%)、38.0%(95%CI 37.3%~38.7%)、20.6%(95%CI 20.0%~21.3%)(P=0.165)。
- ATG-6、ATG-7.5、ATG-9组3年无病生存率分别为53.3%(95%CI 44.9%~63.4%)、51.9%(95%CI 41.0%~65.8%)、63.9%(95%CI 51.9%~78.7%)(P=0.486)。
- ATG-6、ATG-7.5、ATG-9组3年非复发死亡率分别为24.2%(95%CI 23.8%~24.5%)、26.0%(95%CI 25.4%~26.6%)、23.6%(95%CI 26.3%~28.2%)(P=0.955)。
临床怎么用
- 中剂量rATG(7.5 mg/kg)可能是兼顾降低中重度急性GVHD和CMV/EBV感染发生率的选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To compare the clinical efficacy of different doses of rabbit antithymocyte globulin (rATG) in haplo-HSCT in the treatment of hematologic malignancies. Methods: Malignant hematological patients treated at our hospital from March 2013 to December 2018 were retrospectively analyzed. These patients were divided into three groups as per three doses of ATG (6 mg/kg, 7.5 mg/kg, and 9 mg/kg) in the conditioning regimens. The transplant outcomes were compared in terms of the occurrence of acute graft versus host disease (GVHD) , infection, and survival. Results: ①Total 288 patients were enrolled in the study, including 182 men and 106 women, with a median age of 18 (6-62) years. Total 110 patients were diagnosed with acute lymphoblastic leukemia (ALL) , 128 with acute myelogenous leukemia (AML) , 8 with chronic myeloid leukemia (CML) , 28 with myelodysplastic syndrome (MDS) , and 14 with mixed cell leukemia (MAL) . There were 159 patients in the ATG-6 group, 72 in the ATG-7.5 group, and 57 in the ATG-9 group. The median follow-up time of post transplantation was 14 (0.2-74) months. ②The incidence of neutrophil engraftment (96.9% , 97.2% , and 96.5% , respectively) and platelet engraftment (92.5% , 87.5% , and 86% , respectively) did not significantly differ among the ATG-6, ATG-7.5, and ATG-9 groups (P=0.972, P=0.276) . The incidence of grades 2-4 acute GVHD was 14.5% , 11.1% , and 8.8% in the three groups, respectively (P=0.493) , chronic GVHD incidence in the three group was 8.8% , 14.3% and 12.0% , respectively (P=0.493) . The infection rates of CMV and EBV in the ATG-9 group (77.2% and 12.5% ) were significantly higher than those in the ATG-6 (43.3% and 3.5% ) , and ATG -7.5 group (44.4% and 1.5% ) (P<0.001 and P=0.033, respectively) . ③Among the three groups, there were no significant difference in the 3-year overall survival [68.5% (95% CI 60.3% -77.9% ) , 60.1% (95% CI 48.3% -74.8% ) , 64.7% (95% CI 51.9% -80.7% ) ], cumulative incidences of relapse [34.6% (95% CI 34.3% -35.1% ) , 38.0% (95% CI 37.3% -38.7% ) , 20.6% (95% CI 20.0% -21.3% ) ], disease-free survival [53.3% (95% CI 44.9% -63.4% ) , 51.9% (95% CI 41% -65.8% ) , 63.9% (95% CI 51.9% -78.7% ) ] and non-relapse mortality [24.2% (95% CI 23.8% -24.5% ) , 26.0% (95% CI 25.4% -26.6% ) , 23.6% (95% CI 26.3% -28.2% ) ] (P=0.648, P=0.165, and P=0.486 and P=0.955) . Conclusion: Low dose (6 mg/kg) of rATG may increase the risk of grade Ⅱ-Ⅳ aGVHD, and a high dose (9 mg/kg) of ATG could significantly increase the risk of CMV and EBV infection. Median dose (7.5 mg/kg) of ATG is expected to reduce the incidence of moderate to severe aGVHD and viral infections without increasing the mortality. 目的: 比较含不同剂量兔抗人胸腺细胞球蛋白(rATG)预处理方案单倍型造血干细胞移植(haplo-HSCT)对恶性血液病患者的疗效。 方法: 对2013年3月至2018年12月行haplo-HSCT的恶性血液病患者进行回顾性分析,按预处理方案中rATG总量6、7.5、9 mg/kg分为ATG-6、ATG-7.5、ATG-9三组,比较三组患者急性移植物抗宿主病(GVHD)发生率、感染发生率及生存率。 结果: ①纳入288例患者,男182例,女106例,中位年龄18(6~62)岁。急性髓系白血病(AML)128例,急性淋巴细胞白血病(ALL)110例,慢性髓性白血病(CML)8例,骨髓增生异常综合征(MDS)28例,混合细胞白血病(MAL)14例。ATG-6组159例,ATG-7.5组72例,ATG-9组57例。移植后中位随访时间为14.0(0.2~74.0)个月。②ATG-6、ATG-7.5、ATG-9组粒细胞植入率分别为96.9%、97.2%、96.5%(P=0.972),血小板植入率分别为92.5%、87.5%、86.0%(P=0.276),Ⅱ~Ⅳ度急性GVHD发生率分别为14.5%、11.1%、8.8%(P=0.493),慢性GVHD发生率分别为8.8%、14.3%、12.0%(P=0.493)。ATG-9组的CMV、EBV感染率(77.2%、12.5%)均高于ATG-6组(43.3%、3.5%)和ATG-7.5组(44.4%、1.5%)(P<0.001,P=0.033)。③ATG-6、ATG-7.5、ATG-9组移植后3年总生存率分别为68.5%(95%CI 60.3%~77.9%)、60.1%(95%CI 48.3%~74.8%)、64.7%(95%CI 51.9%~80.7%)(P=0.648),3年累积复发率分别为34.6%(95%CI 34.3%~35.1%)、38.0%(95%CI 37.3%~38.7%)、20.6%(95%CI 20.0%~21.3%)(P=0.165),3年无病生存率分别为53.3%(95%CI 44.9%~63.4%)、51.9%(95%CI 41.0%~65.8%)、63.9%(95%CI 51.9%~78.7%)(P=0.486),3年非复发死亡率分别为24.2%(95%CI 23.8%~24.5%)、26.0%(95%CI 25.4%~26.6%)、23.6%(95%CI 26.3%~28.2%)(P=0.955)。 结论: 低剂量rATG(6 mg/kg)可增加haplo-HSCT后Ⅱ~Ⅳ度急性GVHD的发生率,高剂量rATG(9 mg/kg)使CMV、EBV感染风险增加,中剂量ATG(7.5 mg/kg)可能是兼顾降低中重度急性GVHD和CBV/EBV感染发生率的选择。.
引用
- Zhou X, Lu X, Tang L, et al. [Optimization of ATG dose in haploid hematopoietic stem cell transplantation for hematologic malignancies]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 32810962. doi:10.3760/cma.j.issn.0253-2727.2020.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。